Latest news & events

Del Mar's fight against cancer

AUG 17, 2015

DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from NRC-IRAP to Support Expanded Research Program with Lead Product Candidate VAL-083

AUG 17, 2015

DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from NRC-IRAP to Support Expanded Research Program with Lead Product Candidate VAL-083

AUG 17, 2015

DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from NRC-IRAP to Support Expanded Research Program with Lead Product Candidate VAL-083

View all news
DelMar's fight against cancer

Other news & events

Chairman's Blog

Drug Development & Delivery (July/Aug, 2016)

Click here (.pdf)

Business Update Conference Call (May 19, 2016)

Recording: Click here (.mp3)

Slide Deck: Click here (.pdf)

MAY 19, 2016

Reverse Stock Splits & Uplisting

MAY 16, 2016

60 Minutes, Polio Virus for GBM, and the Promise of Chemo-Immunooncology

APR 20, 2016

Mechanism Matters

Breakthrough

VAL-083, our first product candidate, represents a "first-in-class" small molecule chemotherapeutic, which means that the molecular structure of VAL-083 is not an analogue or derivative of other small molecule chemotherapeutics approved for the treatment of cancer.

Learn more about VAL-083

Mission

Our mission is to benefit patients and create shareholder value by rapidly developing and commercializing anti-cancer therapies in orphan cancer indications where patients have failed or are unlikely to respond to modern therapy.

Learn more about DelMar

Pipeline

Our drug discovery research focuses on identifying well-validated clinical and commercial-stage compounds and establishing a scientific rationale for development in modern orphan drug indications.

Learn more about our drug development pipeline